Search results for: Multi-Indication Medicines
Filter search results
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…investigated and identified after initial FDA approval. This is particularly true of oncology drugs, but multi-indication medicines are common across therapy areas. If manufacturers expect a price cut to be…
How long are patients WAITing for new treatments?
2 July 2026
…molecules with multiple indications: those in oncology and immunology together account for almost half of the medicines in the current report, representing 33% and 15% of the sample respectively (OHE…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Multi-indication pricing (MIP) is based on the idea of recognising the value…
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
…the 74 orphan indications approved by the European Medicines Agency (EMA) up to May 2011. The SMC has issued 55 decisions for the 74 orphan indications. Because of resubmissions and…
Compared to what? How the choice of comparator affects new medicines
14 September 2026
…comparator In some therapy areas with no active licensed treatment available, clinical practice may rely on ‘off-label’ medicines, those used for an indication other than the one they are licensed…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…their activity. Multi-Indication Pricing: Pros, Cons and Applicability to the UK by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price for each indication approved for a medicine. The…
Beyond opportunity cost: what are health systems for? The UK–US pharmaceutical agreement and the limits of QALY maximisation
23 October 2026
…to improve the UK commercial environment for medicines taking credit for something that was going to happen anyway. The final, non-binding commitment was around medicines spend. The agreement has often…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…as many orphan medicines compared with the EMA. One potential explanation for this divergence is the EU’s more restricted incentive offer, in addition to the European Medicines Agency (EMA) necessitating…
OHE at ISPOR May 2016: Meet the Team
19 May 2016
…Multi-Indication Pricing: Pros, Cons and its Applicability to the UK OHE Authors: Jorge Mestre-Ferrandiz and Adrian Towse Time and date: Monday 23rd May, 3:45pm. Summary: Multi-indication pricing (MIP) involves setting…